Clinical Trials

Nasopharyngeal Carcinoma

NCT04522050 2023-07-12

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

65 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05563480 2022-12-01

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

90 enrolled

Nasopharyngeal Carcinoma

NCT00997906 2022-09-29

Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC

Phase 2/3 Unknown

172 enrolled

Head and Neck Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT03366415 2022-03-04

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

420 enrolled

Nasopharyngeal Carcinoma

NCT05198531 2022-01-21

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Phase 1/2 Unknown

90 enrolled

Nasopharyngeal Neoplasms

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

91 enrolled

Nasopharyngeal Carcinoma

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

118 enrolled

Nasopharyngeal Carcinoma

NCT02627807 2020-06-16

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Phase NA Unknown

386 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04414566 2020-06-04

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

562 enrolled

Nasopharyngeal Carcinoma

NCT03403829 2019-07-08

Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage

360 enrolled

Nasopharyngeal Carcinoma

NCT03601975 2019-02-04

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

336 enrolled

Nasopharyngeal Carcinoma

NCT03619824 2018-10-09

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

40 enrolled

Nasopharyngeal Neoplasms

NCT03639467 2018-09-18

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

40 enrolled

Nasopharyngeal Carcinoma

NCT01872962 2018-04-24

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

480 enrolled

Nasopharyngeal Carcinoma

NCT02761291 2016-05-16

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

18 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence, Epstein-Barr Virus Infections, Multiple Acyl Coenzyme A Dehydrogenase Deficiency

NCT01915134 2015-01-01

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

362 enrolled

Nasopharyngeal Carcinoma

NCT01417390 2014-03-07

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

80 enrolled

Nasopharyngeal Carcinoma

NCT00004097 2013-09-20

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms

NCT01854203 2013-07-30

NPC

Phase 2/3 Unknown

300 enrolled

Nasopharyngeal Carcinoma

NCT01655628 2012-08-02

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

40 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT00690872 2009-06-29

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

35 enrolled